We used both immunophenotyping and gene expression data when available to classify patients according to T-cell maturation status (Table 1 , Supplementary Figure S1 , Supplementary Table S1 and  Supplementary Table S2 ). Seven patients (324, 432, 706, 716, 748, 791 and 879) clustered as early immature T-ALLs. Five of these tumors strongly expressed CD34 and most had no or weak expression of mature thymocyte markers CD1a, CD4 and CD8. These CD34+/CD1a−/ CD4−/CD8− patients also expressed immature T-cell specific markers such as LMO2, LYL1, BCL2, FLT3, TGFB1 and MYB [1] . Two of these patients (791 and 879), had low expression levels of CD5 (< 75%) and were positive for myeloid or stem-cell markers CD34, HLA-DR, CD13, CD33, CD11b and positive for the T-cell marker cytoplasmic CD3 (cCD3). They expressed LYL1, indicative of an early T-cell precursor ALL (ETP-ALL) phenotype [2] . Twelve patients (340, 341, 437, 544, 547, 636, 693, 727, 743, 744, 759 and 849) positive for CD1a/CD4/CD8 and expressing mature thymocyte markers such as LCK, RAG1, PTCRA or STAT5A [1] were classified as mature T-ALLs (Supplementary Figure S1 and Supplementary Table S1 ). Among these, patients 744 and 849 showed the strongest ectopic expression of the homeobox developmental genes SIX6 and NKX3-1 [1] , and patient 849 showed strong activation of the TAL1 oncogene, further supporting a more advanced (late cortical) stage of maturation. Of note, CD1a+/CD4+ patient 693 highly expressed HOXA genes indicative of T-lineage blockade prior to beta-selection [1] , suggesting an early cortical stage of maturation for this mature T-ALL. Some patients were difficult to classify, such as patient 744 who was classified as mature T-ALL and was the only patient who showed activation of TLX3, typically associated with early cortical cases. However patient 744 was CD34+ and also expressed immature markers such as FLT3 and BMI1.
Chromosomal rearrangements and cryptic events in T-ALL
We identified translocations using Fluorescent In Situ Hybridization (FISH), molecular cytogenetic analyses and RNA-seq data. RNA-seq data confirmed aberrant transcriptional activation of TAL1 for patient 849 but surprisingly showed no up-regulation of this gene in patient 547 (Supplementary Figure S1A) . This is possibly due to intra-tumor heterogeneity of the sample leading to reduced tumor-specific gene expression signals. We could not confirm upregulation of LMO2 and TLX1/HOX11 in patients 759 and 636 because of the lack of expression data. Transcriptome analysis of the two ETP-ALL cases with the t(10;11)(p12:q14) CALM-AF10 translocation revealed aberrant activation of the HOXA cluster [3] , as well as activation of its cofactors BMI1 and MEIS1 (Supplementary Figure S1A and Supplementary Table S2 ). Of note, BMI1 activation leads to CDKN2A inhibition and thus induces cell proliferation, which corroborates with the absence of CDKN2A locus deletions in these immature T-ALL patients [4] . Only one patient (744) showed cryptic activation of TLX3, typically associated with early cortical cases. This patient also had upregulation of BMI1, but no characteristic co-upregulation of HOXA genes was observed, nor did we identify CALM-AF10 or MLL rearrangements typically causing BMI1 activation [3] . Patient 693 presenting the overall strongest activation of the HOXA gene cluster also showed upregulation of oncogenes and T-cell differentiation genes such as NOTCH2, NOTCH3, PTCRA and PIM1 as expected. However no expression of LMO2, LYL1, BCL2 or FLT3 was observed in this patient. Of note, TLX1/HOX11 activation, associated with early cortical T-ALLs and with a favorable prognosis [4] , was not observed in any of the patients investigated here.
Clonal architecture of childhood T-ALL
We used genomic sequencing data (read counts) to study clonal architecture of these childhood T-ALL tumors. For both ETP-ALL patients, we also investigated clonal dynamics from diagnosis (pre-treatment) to relapse. Variant allele frequencies (VAFs) of 48 somatic SNVs and small indels from 66 candidate drivers were estimated from Illumina WES (Methods, mean coverage on targeted region = 120×) and/or ultra-deep targeted re-sequencing data (Methods, mean coverage = 2,500×). Variants identified from RNA-seq data and Sanger sequencing were not considered. Tumor purity was determined either from blast counts at diagnosis or from ASCAT profiles (Table 1) , and was used to adjust VAFs in each tumor (Supplementary Figure S3 and Supplementary Table S3) . Frequencies were not adjusted for copy number variations, which would explain the high somatic variant frequencies at certain loci that overlapped monoallelic deletion events (e.g. WT1 p.R370H (VAF = 0.96)). Once adjusted, 29.2% of identified somatic SNVs and small indels were considered as subclonal as they presented adjusted VAFs ≤ 0.4, and of VAFs ≤ 0.8 for X-linked mutations in males (Supplementary Figure S3A and Supplementary Table S3 ). Variations in common T-ALL drivers (PHF6, FBXW7, JAK1 and JAK3) were mostly clonal (mean VAF = 0.48, standard dev. = 0.10). Interestingly, both variations in JAK1 and JAK3 identified in patient 744 were clonal (VAF = 0.59 and 0.56, respectively), suggesting an early cooperative role as opposed to previous reports of a sequential event with JAK1 acting as first hit and JAK3 contributing to selection and expansion of the JAK1+ subclone [5] . Ras pathway mutations had significantly lower frequencies compared to these common drivers with a mean VAF = 0.33 (standard dev. = 0.11) (p = 0.006, Mann-Whitney-U test). Subclonality of these mutations corroborates previous reports [6] [7] [8] that describe a secondary role for Ras mutations in T-ALL occurring later in tumor progression. SNVs and small indels identified in novel T-ALL genes had different modalities of clonal evolution (Supplementary Figure S3A and Supplementary Table S3 ). For U2AF1, p.R35L was subclonal in all three patients carrying the mutation (mean VAF = 0.24, standard dev. = 0.13), and was therefore likely recently acquired in tumor evolution. On the other hand, mutations in newly identified X chromosome genes USP9X and MED12 (mean = 0.97, SD = 0.04) in patients 194, 744, 791 and 879 had VAFs that were similar to the known driver mutations in PHF6 and KDM6A/UTX (mean = 0.97, SD = 0.05) (p = 1.0000). Given that we had quality relapse data for the two ETP-ALL patients (791 and 879), we investigated the mutational trajectories of known and novel candidate driver genes (Supplementary Figure S3B and Supplementary Figure S3C and Supplementary Table S3 ). The CALM-AF10 translocation carried by both patients at diagnosis was also found in the dominant clone at relapse. In addition to the dominant PHF6 (p.G226fs, VAF = 0.51) and MED12 (p.R1989H, VAF = 0.49) mutations, case 791 also carried subclonal mutations in KMT2C/MLL3 (p.Y816fs, VAF = 0.28) and JAK3 (p.M511I, VAF = 0.13). While patient 791's most subclonal mutations (NOTCH1, VAF = 0.10; JAK3, VAF = 0.13; U2AF1, VAF = 0.09) were lost at relapse, the subclonal tumor cell population carrying the KMT2C/ MLL3 mutation at diagnosis, was selected at relapse with a positive VAF shift from 0.28 to 0.39. On the other hand, X-linked mutations remained clonal with relapse VAFs of 0.46 and 0.44 for PHF6 (p.G226fs) and MED12 (p.R1989H) respectively. This suggested the presence of multiple subclones at diagnosis and subsequent purification at relapse with the emergence of a single founder clone. As for patient 879, almost all relapse mutations were present in the major clone at diagnosis and remained clonal at relapse, including PHF6 (p.R225*, VAF = 0.55 to 0.49), MED12 (p.V167fs, VAF = 0.55 to 0.49), JAK3 (p.L857P, VAF = 0.54 to 0.53) and FBXW7 (p.W425C, VAF = 0.55 to 0.45). Only WT1 (p.V167fs) was counter-selected at relapse and presented a negative VAF shift from 0.49 to 0.29. Overall, subclones present in both patients at diagnosis underwent a putative selection illustrated by the loss of subclones in 791 with the emergence of a fitter dominant clone at relapse carrying KMT2C p.Y816fs, and loss of a WT1 p.V167fs subclone in 879. Interestingly, no additional relapse-specific events were identified in these cases. Given that MED12 positive cells showed clonal equilibrium, it was difficult to evaluate their relapse potential, however their maintenance as dominant population in both cases suggests potential involvement in the process.
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